The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages

  Ji, Shundong ^a   Jiang, Miao ^a   Yan, Bin ^a   Shen, Fei ^a   He, Yang ^a   Wan, Aini ^b   Xia, Lijun ^a,c   Ruan, Changgeng ^a   Zhao, Yiming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b JIANGNAN UNIVERSITY   (China)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Collagen; Monoclonal antibody; Platelet; Platelet aggregation; Thrombosis; Von Willebrand factor (VWF)

Indexed keywords

COLLAGEN TYPE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SZ 123; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ANTITHROMBOCYTIC AGENT; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CELL CLONE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; EXPRESSION VECTOR; FEMALE; FEMORAL ARTERY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MALE; MOLECULAR CLONING; NONHUMAN; RHESUS MONKEY; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; METABOLISM; MOUSE; PATHOLOGY; PROTEIN DOMAIN; THROMBOCYTE; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CHO CELLS; COLLAGEN TYPE III; CRICETULUS; FEMALE; HUMANS; MACACA MULATTA; MALE; MICE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PROTEIN DOMAINS; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 85019942585     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-017-0475-2     Document Type: Article

References (31)

1. Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, Deckmyn H. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost. 2008;100(4):670-7.
2. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ. Structures of glycoprotein Ib alpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-9.
3. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-50.
4. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the ‘Magic Bullet’. Nat Rev Drug Discov. 2003;2(10):775-89.
5. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Haematol. 2008;142(4):515-28.
6. Yeh CH, Wang WC, Hsieh TT, Huang TF. Agkistin a snake venom-derived glycoprotein Ib antagonist, disrupts von Willebrand factor-endothelial cell interaction and inhibits angiogenesis. J Biol Chem. 2000;275(25):18615-18.
7. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, Novák L, Harsfalvi J, Deckmyn H, Kotzé HF. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000;20(5):1347-53.
8. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprortein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22(2):323-8.
9. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122(1):165-71.
10. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Antihuman vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res. 2001;101(5):395-404.
11. Kageyama S, Yamamoto H, Nakazawa H, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22(1):187-92.
12. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99(10):3623-8.
13. De Meyer SF, Staelens S, Badenhorst PN, Pieters H, Lamprecht S, Roodt J, et al. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor-collagen interaction in baboons. Thromb Haemost. 2007;98(6):1343-9.
14. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116(23):2678-86.
15. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke. 2011;116(23):2678-86.
16. Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost. 2006;95(3):469-75.
17. Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, Xu J, Porter TJ, Huang Q. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost. 2007;98(2):397-405.
18. Lenting PJ, Denis CV, Wohner N. Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target. Curr Vasc Pharmacol. 2013;11(4):448-56.
19. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-93.
20. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-59.
21. Qu L, Jiang M, Qiu W, Lu S, Zhao Y, Xia L, Ruan C, Zhao Y. Assessment of the diagnostic value of plasma levels, activities, and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction. Clin Appl Thromb Hemost. 2016;22(3):252-9.
22. Zhao Y, Dong N, Shen F, Xie L, He Y, Liu F, Ruan C. Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost. 2007;5(9):1963-70.
23. Zhao YM, Jiang M, Ji SD, He Y, Shen F, Li XM, Ruan CG. Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochem Pharmacol. 2013;85(7):945-53.
24. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3-10.
25. Ruan CG, Xi XD, Gu JM. Studies on monoclonal antibodies to human von Willebrand factor. Zhonghua Nei Ke Za Zhi. 1986;25(11):547-50.
26. Jia Q, Wu H, Zhou X, Gao J, Zhao W, Aziz J, Wei J, Hou L, Wu S, Zhang Y, Dong X, Huang Y, Jin W, Zhu H, Zhao X, Huang C, Xing L, Li L, Ma J, Liu X, Tao R, Ye S, Song Y, Song L, Chen G, Du C, Zhang X, Li B, Wang Y, Yang W, Rishton G, Teng Y, Leng G, Li L, Liu W, Cheng L, Liang Q, Li Z, Zhang X, Zuo Y, Chen W, Li H, Hui MM. A “GC-rich” method for mammalian gene expression: a dominant role of non-coding DNA GC content in regulation of mammalian gene expression. Sci China Life Sci. 2010;53(1):94-10.
27. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(6 Suppl):IV3-14.
28. Yin J, Ma Z, Su J, Wang JW, Zhao X, Ling J, Bai X, Ouyang W, Wang Z, Yu Z, Ruan C. Mutations in the D1 domain of von Willebrand factor impair their propeptide-dependent multimerization, intracellular trafficking and secretion. J Hematol Oncol. 2015;8:73-7.
29. Portolano N, Watson PJ, Fairall L, Millard CJ, Milano CP, Song Y, Cowley SM, Schwabe JW. Recombinant protein expression for structural biology in HEK 293 F suspension cells: a novel and accessible approach. J Vis Exp. 2014;92:e51897-907.
30. Omasa T, Onitsuka M, Kim WD. Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr Pharm Biotechnol. 2010;11(3):233-40.
31. Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol. 2005;68(3):283-91.